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QA check during treatment and this study is preliminary to DC 
use for in vivo dosimetry. 
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Purpose/Objective: Total Skin Electron Irradiation (TSEI) is a 
complex technique which requires non-standard 
measurements and dosimetric procedures. At our center, the 
six-dual-field approach is implemented for this treatment. 
The purpose of this work is to validate the measured 
dosimetry data by Monte Carlo (MC) simulations. 
Materials and Methods: 6 MeV beam from Elekta Precise 
linac operated in High-Dose-Rate (HDR) mode is used fort 
TSEI treatments. The EGSnrc code package was used for MC 
simulation. First, the incident electron beam parameters 
(energy spectrum, FWHM) were adjusted to match the 
measured data (PDD and profile) at SSD=100 cm for 40x40 
open field. These parameters were then used to calculate 
dose distributions at the treatment distance of 400 cm. 
BEAMnrc code was used to generate the phase-space file in a 
plane at the exit from the linac head (at the mylar). This file 
was used in DOSXYZnrc code to calculate PDDs, profiles and 
output in a water phantom at SSD= 400 cm from a single 
beam. Optimal gantry angle was determined. Full treatment 
with 6 dual fields was simulated on the CT-based 
anthropomorphic phantom. MC calculations were compared 
with the available set of measurements used in clinical 
practice. 
Results: The results of our Monte Carlo calculations were 
found to be in general agreement with the measurements, 
providing a promising tool for further studies of dose 
distribution calculations in TSEI. For one direct field at the 
treatment distance, calculated PDD was within 3%/1mm 
agreement and calculated profile was within 2% agreement 
with the measurements. The calculated output at the 
treatment distance was 3% lower than the measured output. 
The optimal gantry angle providing the best flatness of the 
surface dose was confirmed to be 17 degrees. Depth doses for 
the full treatment calculated in the anthropomorphic 
phantom agreed with the measurements within 3%/1mm. 
Conclusions: The measured dosimetry data used for TSEI 
calculations are validated by MC simulations. This work also 
indicates that simulations can complement and/or replace 
extensive experimental measurements needed for 
commissioning of TSEI technique.  
   
EP-1393   
A quick measure equipment characterization for the 
comissioning of Varian¥s Enhanced Dynamic Wedges 
C. Quilis1, J. Saez1, D. Lambisto1, C. Camacho1, A. Herreros1, 
J. Garcia - Miguel1, A. Biete1 
1Hospital Clínic, Radiation Oncology, Barcelona, Spain  
 
Purpose/Objective: For the comissioning as well as for the 
quality control (QC) of enhanced dynamic wedges (EDW) two 
devices are commonly used: a system of linear waterproof 
detectors for relative dosimetry verification, and ionization 
chambers for the verification of wedge factors. Hereby we 
study the posibility of executing this process with a quick 
measure equipment. 
Materials and Methods: The PTW StarCheck device is a linear 
arrangement of small volume ionization chambers (0.053 cc) 
separated 3 mm (except central chamber and the second 
chamber) in the left-right and head-feet directions. The 
manufacturer provides the equipment with a calibration 
energy Cobalt factor and a calibration matrix which adjusts 
the gain of the other cameras respect the central chamber. 
We compared the values obtained with the ionization 
chamber and StarCheck for energies of 6 MV and 18 MV 
(measurement conditions: SSD 100 cm and depths 5 cm and 7 
cm respectively): 
• EDW factors for all angles for the fields: 4x4 cm2, 10x10 
cm2, and 20x20 cm2. 
• EDW angle obtained with the Schmidt method for all 
possible combinations of wedge angles and field size. 
• Wedge angle independence depending on the orientation of 
the wedge. 
Finally, we evaluated the effect of interrupting the execution 
of the dynamic wedge by comparing radiation without 
interruption against the added amount of radiation 
interrupted for different values of monitor units: 25, 50, 100 
and 200. 
Results: The StarCheck response linearity is brilliant: linear 
correlation coefficient of 0.999998 for the reading in the 
central chamber vs the Farmer camera with readings in the 
range from 2 to 400 UM. The equivalent depth obtained is 8.9 
mm compatible with the value of 8.5 mm supplied by the 
manufacturer. StarCheck obtained EDW factors are within 
0.5% compared to those obtained with the reference Farmer 
camera for all combinations of energy (6 MV and 18), fields 
(4x4, 10x10, 20x20 cm2) and wedge angle (10, 15, 20, 25, 30, 
45 and 60). The wedge angles measured by StarCheck match, 
with a maximum difference of 1 degree, those obtained with 
a Semi-Flex camera in a water phantom for all wedges and 
fields 10x10 cm2 and 20x20 cm2. Considerable differences in 
the angles have been obtained between StarCheck and semi-
flex camera for dynamic wedges below 30 degrees and the 
field 4x4 cm2. The interruptions analysis shows that in 
treatments with EDW with less than 50 UM a disruption can 
cause an over-dose of approximately 2%, regardless of 
whether the interruption occurs during static wedge phase or 
during the movement of the jaw and regardless of the angle 
wedge. 
Conclusions: This study allows us to assure that it is possible 
to achieve a significant part of the comissioning of EDW with 
just a quick measurement device. 
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Purpose/Objective: We retrospectively analyzed our five 
years experience with patient-specific VMAT QA using the 
PTW seven29/Octavius system and reported our institutional 
guidelines and action limits for VMAT delivery.  
Materials and Methods: Since June 2009, 1001 patients were 
treated with Elekta VMAT technique at our institution. 
Treatment plans were re-grouped according to treatment 
technique and disease sites: (1) 437 patients with high-
modulated complex treatments for head-neck, rectal, 
endometrial, brain tumours and other sites, all optimized 
with Masterplan Oncentra TPS with Simultaneous Integrated 
Boost strategy in dual-arc modality; (2) 248 patients with 
prostate tumours and (3) 316 patients with bone, liver, lung, 
abdominal and pelvic metastasis treated with high-dose 
extracranial stereotactic radiotherapy (SBRT). Group 2/3 
plans were optimized with anatomy-based Ergo++ TPS and 
treated with one arc. The absolute doses were measured 
utilizing the PTW Seven29 ion-chamber array and the 
Octavius phantom. VMAT plans were recalculated on 
phantoms representing the Octavius geometry and density; 
for each arc the doses were measured both on coronal and 
sagittal planes, for a total of 2876 measurements (in groups 1 
and 2/3, each plan underwent four and two measurements, 
respectively). Agreement of measured and predicted doses 
were evaluated using 3%(global)/3mm γ-analysis. Three 
scalar metrics were evaluated for each measurement: (a) 
percentage of points with gamma value less than one (Pg<1), 
(b) mean gamma (γmean), and (c) maximum gamma (γmax). 
Gamma results were evaluated according to treatment 
technique and disease sites and reported for each arc 
individually and on a per patient-basis. 
Results: Table 1 shows the overall γ-analysis results for all 
patients with associated confidence limits. γ pass-rate values 
significantly depend on plan complexity. For the patients in 
group (1), average Pg<1, γmean and γmax were 94.8% ± 3.8%, 0.39 
± 0.08 and 1.83 ± 0.55, respectively. These values reached 
99.1% ± 1.9%, 0.38 ± 0.08 and 0.99 ± 0.25 values in group (2) 
and 98.3% ± 2.7%, 0.32 ± 0.09 and 1.13 ± 0.45 values in group 
(3). On a per-patient basis, our local confidence limits for Pg<1 
were determined to be 10.0%, 4.0%, and 6.6%, for patients in 
group 1, 2 and 3, respectively. 
 
 
 
Conclusions: This comprehensive study shows that PTW 
seven29/Octavius system allows a reliable and accurate 
dosimetric procedure for VMAT QA, benefiting from all the 
advantages of ionization chamber absolute dosimetry. 
Despite the increased complexity in VMAT treatments, our 
local confidence limits were comparable to those of AAPM TG 
119. 
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Purpose/Objective: VMAT delivers radiation via dynamic 
multileaf collimator (MLC) motion, and allows for variable 
dose rates, gantry speed modulation, and collimator rotation. 
It is, therefore, patient-specific quality assurance (QA) for 
VMAT plans is important in confirming dose distribution. The 
COMPASS® system allows for 3D dosimetric quality assurance 
using MatriXX-specific software and the MatriXX mounted to 
the gantry with a gantry angle sensor. In this study, the 
retrospective investigation of the QA results using COMPASS 
for head and neck (H&N) VMAT cases. 
Materials and Methods: VMAT patient plans were delivered 
to the MatriXX and used to verify the 3D dose distribution 
calculated by COMPASS. QA results of 65 head and neck 
patients which were treated in our clinic with 
TrueBeam/TrubeamSTX machine consist of the 
nasopharyngeal, larynx and oral cavity tumors were analyzed. 
Compass system with MatriXX can provide an accurate three-
dimensional quantitative analysis of dose delivery. Dose 
distribution and 3D anatomical site dose differences using 
DVH were evaluated by comparing the measurements and the 
treatment planning system (TPS) calculations by using AAA 
algorithm at the Eclipse TPS. Furthermore, the investigation 
of the TPS and COMPASS dose calculation based on the 
Collapse Cone Algorithm was assessed. The COMPASS and the 
measurement dose distributions agreement was tried o obtain 
with that of a treatment planning system by gamma analysis 
(criteria; 3 mm/3%)a and the volumetric results of the 
critical organs such as spinalcord was evaluated by average 
dose value with 3% criteria. 
Results: Compass system was very sensitive to the MLC and 
dose error caused by machine. This system allows to asses 3D 
anatomical based dose difference between measurement and 
planning dose. We found that except 5 cases inside the data 
sets the relative dose differences agreement within the dose 
volume criteria for spinalcord. All parotid glands dose 
differences were inside the dose acceptance criteria except a 
case which shows 4,03%. For all cases, CTV and GTV dose 
agreement was archived inside the gamma criteria. 
Conclusions: The COMPASS system can be expected to be 
used for traditional QA methods in clinical routine for QA of 
VMAT plans. The Compass allows anatomical dose distribution 
evaluation to decide acceptable treatment plan. 
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